Patent: 10,668,053
✉ Email this page to a colleague
Summary for Patent: 10,668,053
Title: | Tolerogenic synthetic nanocarriers to reduce or prevent anaphylaxis in response to a non-allergenic antigen |
Abstract: | This invention relates to methods for reducing or preventing anaphylaxis to non-allergenic antigens with compositions comprising immunosuppressants, and related compositions. |
Inventor(s): | Maldonado; Roberto A. (Jamaica Plain, MA) |
Assignee: | Selecta Biosciences, Inc. (Watertown, MA) |
Application Number: | 14/269,048 |
Patent Claims: | see list of patent claims |
Details for Patent 10,668,053
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genzyme Corporation | CEREZYME | imiglucerase | For Injection | 020367 | 05/23/1994 | ⤷ Try a Trial | 2033-05-03 |
Genzyme Corporation | CEREZYME | imiglucerase | For Injection | 020367 | 09/22/1999 | ⤷ Try a Trial | 2033-05-03 |
Microbix Biosystems Inc. | KINLYTIC | urokinase | For Injection | 021846 | 01/16/1978 | ⤷ Try a Trial | 2033-05-03 |
Pfizer Inc. | ELELYSO | taliglucerase alfa | For Injection | 022458 | 05/01/2012 | ⤷ Try a Trial | 2033-05-03 |
Takeda Pharmaceuticals U.s.a., Inc. | VPRIV | velaglucerase alfa | For Injection | 022575 | 02/26/2010 | ⤷ Try a Trial | 2033-05-03 |
Amgen, Inc. | EPOGEN/PROCRIT | epoetin alfa | Injection | 103234 | 06/01/1989 | ⤷ Try a Trial | 2033-05-03 |
Amgen, Inc. | EPOGEN/PROCRIT | epoetin alfa | Injection | 103234 | ⤷ Try a Trial | 2033-05-03 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |